Breaking News Instant updates and real-time market news.

MU

Micron

$25.70

0.52 (2.07%)

, F

Ford

$12.54

0.01 (0.08%)

07:36
03/14/17
03/14
07:36
03/14/17
07:36

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Micron (MU), Ford (F), Target (TGT), Sirius XM (SIRI), Marvell (MRVL), Dollar Tree (DLTR), Rio Tinto (RIO), Aurinia Pharmaceuticals (AUPH), Alexion (ALXN), and ServiceMaster (SERV).

MU

Micron

$25.70

0.52 (2.07%)

F

Ford

$12.54

0.01 (0.08%)

TGT

Target

$55.19

-0.17 (-0.31%)

SIRI

SiriusXM

$5.44

0.25 (4.82%)

MRVL

Marvell

$16.27

-0.12 (-0.73%)

DLTR

Dollar Tree

$74.58

-0.48 (-0.64%)

RIO

Rio Tinto

$40.85

1.46 (3.71%)

AUPH

Aurinia Pharmaceuticals

$10.54

2.04 (24.00%)

ALXN

Alexion

$124.74

-2.57 (-2.02%)

SERV

ServiceMaster

$40.25

0.11 (0.27%)

  • 14

    Mar

  • 19

    Mar

  • 20

    Mar

  • 22

    Mar

  • 23

    Mar

  • 23

    Mar

  • 23

    Mar

  • 04

    Apr

  • 05

    Apr

  • 23

    Oct

  • 14

    Mar

MU Micron
$25.70

0.52 (2.07%)

03/01/17
03/01/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Micron (MU) upgraded to Buy from Neutral at Goldman with analyst Mark Delaney saying the potential for near-term earnings upside from better margins presents a "tactical opportunity." 2. Owens Corning (OC) upgraded to Buy from Neutral at BofA/Merrill with analyst John Lovallo citing increased confidence that industry is operating line capacity utilization could increase to the mid-90% range in the second half 2017/2018 from roughly 90% today. Following management meetings yesterday, Lovallo raised estimates to reflect increased confidence in a positive price inflection in the insulation business and said Composites pricing could rise more than expected in 2017. 3. Williams (WMB) upgraded to Conviction Buy from Buy at Goldman with analyst Theodore Durbin citing the 38% total return potential to his unchanged price target of $38. The market is not appreciating the company's "visible, low-risk" organic growth and "strong" free cash flow generation, Durbin tells investors in a research note. 4. GMS Inc. (GMS) upgraded to Outperform from Neutral at Baird with analyst David Manthey citing continued construction tailwinds, industry share gains, solid operating leverage potential and strong M&A activity. Manthey raised his price target to $36 from $32. 5. Marvell (MRVL) upgraded to Neutral from Sell at Goldman with analyst Mark Delaney citing improved hard disk drive demand trends. The analyst believes consensus estimates can move higher when Marvell reports results on March 2 and upped his price target for the shares to $16 from $12. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/02/17
NEED
03/02/17
NO CHANGE
Target $42
NEED
Buy
Micron price target raised to $42 from $33 at Needham
Needham analyst Rajvindra Gill raised his price target on Micron to $42 following the company's positive preannouncement.
03/02/17
STFL
03/02/17
NO CHANGE
Target $40
STFL
Buy
Micron price target raised to $40 from $34 at Stifel
Stifel analyst Kevin Cassidy raised his price target on Micron to $40 after the company raised its guidance for its Q2 earnings, revenue and gross margin. The firm has a Buy rating on Micron shares.
03/02/17
GSCO
03/02/17
NO CHANGE
GSCO
Buy
Micron positive preannouncement supports near-term earnings upside, says Goldman
Goldman analyst Mark Delaney said Micron's positive preannouncement supports his view of near-term earnings upside from better margins. Delaney expects additional earnings upside in the May and August quarters given the timing lag for better market pricing to impact contracts. The analyst has a Buy rating and a $29 price target on Micron shares.
F Ford
$12.54

0.01 (0.08%)

02/26/17
GSCO
02/26/17
DOWNGRADE
Target $41
GSCO
Neutral
Allison Transmission downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Jerry Revich downgraded Allison Transmission (ALSN) to Neutral from Buy with an unchanged price target of $41. The manufacturer of fully-automatic transmissions for trucks closed Friday up 24c to $36.79. The stock, currently trading at an 8% free cash flow yield versus 13% in Sept. 2013, offers limited upside and a balanced risk/reward profile, Revich tells investors in a research note. He also believes that the range of competitive transmission options is rising. Ford (F) is gaining share with its automotive engine and transmission, Revich points out.
02/10/17
JEFF
02/10/17
UPGRADE
Target $12
JEFF
Hold
Ford upgraded to Hold from Underperform at Jefferies
Jefferies analyst Philippe Houchois upgraded Ford Motor to Hold saying the company's "bad news" in the last six months has been sufficiently priced into the shares. While cyclical risks remain, Ford should benefit the most of the big three from infrastructure spending, border adjusted tax reform and exposure to a Russian auto recovery, Houchois tells investors in a research note. He raised his price target for the shares to $12 from $10.
02/10/17
JEFF
02/10/17
NO CHANGE
Target $36
JEFF
Hold
Jefferies switches preference to Ford from General Motors
Jefferies analyst Philippe Houchois switched his preference to Ford Motor (F) shares from General Motors (GM) after upgrading the former to Hold. The analyst keeps a Hold rating on GM with a $36 price target. Matching last years' $6B-plus adjusted free cash "is looking challenging," Houchois tells investors in a research note.
02/10/17
02/10/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ford (F) upgraded to Hold from Underperform at Jefferies with analyst Philippe Houchois upgraded Ford (F) Motor to Hold saying the company's "bad news" in the last six months has been sufficiently priced into the shares. While cyclical risks remain, Ford should benefit the most of the big three from infrastructure spending, border adjusted tax reform and exposure to a Russian auto recovery, Houchois tells investors in a research note. He raised his price target for the shares to $12 from $10. 2. CSX (CSX) upgraded to Outperform from Market Perform at Avondale. 3. Jack in the Box (JACK) upgraded to Buy from Hold at SunTrust with analyst Jake Bartlett saying he expects the company to benefit from fewer discounts in the sector and market share gains going forward. 4. Cigna (CI) upgraded to Outperform from Sector Perform at RBC Capital with analyst Frank Morgan saying the company is well positioned as a standalone entity. The analyst believes Cigna has "multiple positive levers" to drive earnings higher and sees a likelihood for "significant" capital deployment. Morgan raised his price target for the shares to $172 from $151. 5. Enerplus (ERF) upgraded to Outperform from Market Perform at BMO Capital with analyst Ray Kwan citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TGT Target
$55.19

-0.17 (-0.31%)

03/01/17
LEHM
03/01/17
NO CHANGE
Target $50
LEHM
Underweight
Target price target lowered to $50 from $60 at Barclays
Barclays analyst Matthew McClintock lowered his price target for Target to $50 saying the valuation should trade at a discount to historical levels. The company's plan only calls for stabilization in the business starting in 2019, with 2017 being an investment phase and 2018 being a transition phase, McClintock tells investors in a post-earnings research note. The analyst keeps an Underweight rating on shares of Target.
03/01/17
WOLF
03/01/17
DOWNGRADE
WOLF
Underperform
Target downgraded to Underperform from Peer Perform at Wolfe Research
03/01/17
BERN
03/01/17
NO CHANGE
BERN
Dollar General unlikely to be affected by Target price cuts, says Bernstein
Bernstein analyst Brandon Fletcher says that Dollar General's (DG) stock fell due to worries about Target's (TGT) price cuts. however, Fletcher does not believe that there is significant overlap between the two companies' customer base or between their geographic markets, so he does not expect Dollar General to be signficantly affected by Targets moves. The analyst keeps a $91 price target and an Outperform rating on Dollar General.
03/01/17
GSCO
03/01/17
NO CHANGE
Target $53
GSCO
Sell
Target price target lowered to $53 from $67 at Goldman
Goldman analyst Matthew Fassler maintained his Sell rating on Target (TGT) saying its categories, markets, and customers are likely to move to more online options, including Amazon.com (AMZN), and it will be difficult for Target to establish price or assortment edge on commoditized goods. He questions if a direct distribution model focused around stores optimizes costs versus peers and how it will weather a move toward Everyday low prices and away from promotions. Fassler lowered his price target to $53 from $67 and said he expects earnings erosion to continue beyond the first year of investment.
SIRI SiriusXM
$5.44

0.25 (4.82%)

11/22/16
BTIG
11/22/16
INITIATION
BTIG
Neutral
Sirius XM initiated with a Neutral at BTIG
BTIG analyst Brandon Ross initiated Sirius XM (SIRI) with a Neutral saying he prefers to own the Liberty Sirius (LSXMK) tracking stock, as it offers better risk/reward.
12/06/16
OPCO
12/06/16
UPGRADE
OPCO
Outperform
Opco upgrades Pandora, says merger with Sirius makes sense
Oppenheimer analyst Jason Helfstein upgraded Pandora Media (P) to Outperform from Perform with an $18 price target. The streaming music service closed yesterday up 4c to $13.37. A combination with Sirius XM (SIRI) makes sense at $18-$21 per share, Helfstein tells investors in a research note. The analyst sees "significant" demographic and operating synergies between the two companies and views a Pandora buyout as a "legitimate possibility" following press reports indicating Sirius has renewed interest.
03/03/17
EVER
03/03/17
DOWNGRADE
Target $5.5
EVER
In Line
Sirius XM downgraded to In Line from Buy at Evercore ISI
Evercore ISI changed its rating system to Outperform, In Line and Underperform. Analyst Vijay Jayant changed Sirius XM's (SIRI) to In line and shares have 7% upside to his new price target of $5.50, upped from $5.35, reflecting a slightly higher probability for tax reform, as well as greater confidence that the company isn't likely to enter into M&A without attractive terms.
01/11/17
MACQ
01/11/17
NO CHANGE
Target $5
MACQ
Outperform
Sirius XM attractive with or without Pandora acquisition, says Macquarie
Macquarie analyst Amy Yong believes that Sirius XM (SIRI) shares are attractive whether or not the company were to pursue an acquisition of Pandora (P), but that such a deal could refresh the long-term story and rerate the shares. She estimates the purchase of Pandora, assuming a $15 per share offer, would dilute Sirius XM's 2017 free cash flow per share by about 3%, adding Sirius XM's balance sheet "could easily absorb an all-cash or mostly-cash deal." Meanwhile, Sirius and parent Liberty could strengthen Pandora's execution while the satellite-digital combination and the addition of Pandora's over 80M active users "could single-handedly resolve Sirius XM's digital strategy," argues Yong, who raised her price target on Sirius shares to $5 from $4.85 and maintains an Outperform rating on the stock.
MRVL Marvell
$16.27

-0.12 (-0.73%)

03/13/17
UBSW
03/13/17
NO CHANGE
Target $21
UBSW
Buy
Marvell one of least expensive semiconductor names, says UBS
UBS analyst Stephen Chin said Marvell is one of the least expensive names in the semiconductor space based on valuation. The analyst attended the company's first ever analyst meeting and now sees a solid path to long term sales growth of over 6%, citing its new products in storage and cloud sales in its networking segment. Chin reiterated his Buy rating and $21 price target on Marvell shares.
03/13/17
03/13/17
UPGRADE
Target $21

Buy
Marvell upgraded to Buy from Hold at Needham
As previously reported, Needham analyst N. Quinn Bolton upgraded Marvell to Buy from Hold, with a $21 price target, following the company's inaugural analyst day, in which management laid out its strategy to grow revenue, further streamline operations and increase capital returns to shareholders. The analyst believes increasing capital returns to shareholders coupled with the potential for accretive M&A further enhance potential upside in Marvell shares.
03/13/17
NEED
03/13/17
UPGRADE
NEED
Buy
Marvell upgraded to Buy from Hold at Needham
03/13/17
03/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Needham analyst N. Quinn Bolton upgraded Marvell (MRVL) to Buy from Hold, with a $21 price target, following the company's inaugural analyst day, in which management laid out its strategy to grow revenue, further streamline operations and increase capital returns to shareholders. 2. Raymond James analyst Simon Leopold upgraded Finisar (FNSR) to Strong Buy from Outperform citing the 23% selloff in shares on Friday. The analyst believes the company's execution issues are "either misunderstood or exaggerated." He sees upside to estimates and has a $40 price target for the shares. 3. Morgan Stanley analyst Rajeev Lalwani upgraded Rockwell Collins (COL) to Overweight from Equal Weight and raised his price target for the shares to $121 from $94. 4. Citi analyst Michael Rollins upgraded Equinix (EQIX) to Buy from Neutral citing prospects for faster growth from the company's European portfolio as well as acquisitions. The analyst raised his price target for the shares to $435. 5. Goldman Sachs analyst Terence Flynn upgraded Blueprint Medicines (BPMC) to Buy from Neutral citing pipeline momentum following last year's data readouts. The analyst expects a "steady flow" of readouts at conferences this year from the extension phases of trials and clarity on potential registration paths. He upped his price target for the shares to $52 from $35. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
DLTR Dollar Tree
$74.58

-0.48 (-0.64%)

01/19/17
01/19/17
DOWNGRADE
Target $97

Buy
Dollar Tree removed from Conviction Buy List on sluggish trends at Goldman
As previously reported, Goldman removed Dollar Tree from the Conviction Buy List and lowered its price target to $97 from $102. Analyst Stephen Tanal expects top line trends to remain sluggish in 2017 due to capacity growth, continued food deflation, and a "hyper-competitive" environment that will likely keep same-store-sales subdued. Tanal expects costs to accelerate from minimum wage hikes, manager salary increases, and the rising costs of diesel fuel but stays Buy rated due to deal synergies that drive high visible earnings growth and benefits from an improving low-income consumer.
12/07/16
LOOP
12/07/16
INITIATION
LOOP
Hold
Dollar Tree initiated with a Hold at Loop Capital
02/06/17
BERN
02/06/17
INITIATION
Target $63
BERN
Underperform
Dollar Tree initiated with an Underperform at Bernstein
Target $63.
01/19/17
GSCO
01/19/17
DOWNGRADE
GSCO
Buy
Dollar Tree downgraded to Buy from Conviction Buy at Goldman
RIO Rio Tinto
$40.85

1.46 (3.71%)

12/07/16
FBCO
12/07/16
UPGRADE
FBCO
Outperform
Rio Tinto upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst James Gurry upgraded Rio Tinto to Outperform with a priced target of GBP 3,600.
12/01/16
ARGS
12/01/16
NO CHANGE
ARGS
Rio Tinto price target raised to $44 from $36 at Argus
Argus analyst John Eade raised his price target on Rio Tinto citing commodity price gains. The analyst keeps a Buy rating on the shares.
12/05/16
SBSH
12/05/16
UPGRADE
SBSH
Neutral
Rio Tinto upgraded to Neutral from Sell at Citi
Citi analyst Heath Jansen upgraded Rio Tinto to Neutral after double upgrading his Metals & Mining sector view from bearish to bullish. Changes in company behavior could lead to value creation over the next few years, Jansen tells investors in a research note. The analyst has a "more robust" outlook for 2017 for the commodity complex. He raised his price target for Rio shares to GBP 33 from GBP 25.50.
12/05/16
SBSH
12/05/16
UPGRADE
SBSH
Neutral
Rio Tinto upgraded to Neutral from Sell at Citi
AUPH Aurinia Pharmaceuticals
$10.54

2.04 (24.00%)

12/30/16
HCWC
12/30/16
NO CHANGE
Target $8
HCWC
Buy
Aurinia Pharmaceuticals target lowered to $8 from $10 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered his price target for Aurinia Pharmaceuticals to $8 to reflect dilution from the company's just closed equity offering. The financing removes the funding overhang, Arce tells investors in a research note. Aurinia expects its current cash is now sufficient to get it through 2017, which allows it "enough time to be thoughtful in selecting and securing additional, non-dilutive funding options, including out-licensing deals," the analyst contends. He keeps a Buy rating on the shares.
03/06/17
FBRC
03/06/17
NO CHANGE
FBRC
FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."
03/03/17
HCWC
03/03/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $8 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target on Aurinia Pharmaceuticals to $12 from $8 after the company reported that treatment of lupus nephritis with voclosporin demonstrated a substantial further improvement at 48 weeks. Given this type of "rare" treatment effect change over time, Arce said his conviction has increased that voclosporin can quickly emerge as the new standard-of-care in lupus nephritis treatment and he keeps a Buy rating on Aurinia shares.
03/02/17
LEER
03/02/17
NO CHANGE
LEER
Aurinia Pharmaceuticals price target raised to $11 from $7 at Leerink
ALXN Alexion
$124.74

-2.57 (-2.02%)

03/07/17
BMOC
03/07/17
NO CHANGE
BMOC
RA Pharmaceuticals price target raised to $31 from $24 at BMO Capital
BMO Capital analyst M. Ian Somaiya expects data from an open-label Phase II trial in PNH patients to show that the once daily subQ formulation of RA's RA101495 drug is viable and that the drug can compete effectively with Alexion's (ALXN) Soliris. Somaiya keeps an Outperform rating on RA.
03/13/17
LEER
03/13/17
NO CHANGE
Target $208
LEER
Outperform
Alexion price target lowered to $208 from $217 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Alexion to $208 from $217 after the company disclosed the sBLA for Soliris in myasthenia gravis was accepted by the FDA with a PDUFA date of October 23, 2017, and clarified that the timing for its neuromyelitis optica Phase 3 results will be 2018, not 2017. The analyst noted that both updates delay the launch and ramp of revenues for these indications in his model, as he previously assumed myasthenia gravis launched in mid-2017 and neuromyelitis optica launched in 2018. He reiterates an Outperform rating on the shares.
02/16/17
GSCO
02/16/17
DOWNGRADE
Target $417
GSCO
Neutral
Regeneron downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Terence Flynn downgraded Regeneron Pharmaceuticals (REGN) to Neutral from Buy citing valuation with the stock within 9% of his unchanged $417 price target. The analyst sees less upside potential relative to Regeneron's large-cap peers Amgen (AMGN) and Alexion (ALXN). Flynn adds that his revenue estimates for Regeneron's 2018-2020 are no longer above consensus following the PCSK9 litigation and recent Eylea guidance. The stock closed yesterday up $7.47 to $384.00.
03/01/17
NOMU
03/01/17
INITIATION
NOMU
Buy
Alexion initiated with a Buy at Nomura
Nomura initiated Alexion with a Buy and an $148 price target.
SERV ServiceMaster
$40.25

0.11 (0.27%)

02/24/17
FBCO
02/24/17
NO CHANGE
Target $51
FBCO
Outperform
ServiceMaster price target to $51 from $43 at Credit Suisse
Credit Suisse analyst Anjaneya Singh raised his price target for ServiceMaster to $51 from $43 saying guidance is de-risked as focus turns to TMX growth acceleration in 2H17. With AHS continuing to perform well, and the M&A as well as shareholder return opportunity beginning to trickle in, the analyst sees plenty of drivers for upside to consensus estimates. He continues to find ServiceMaster's defensiveness to be attractive. Singh reiterates an Outperform rating on the shares.
01/19/17
FBCO
01/19/17
NO CHANGE
Target $43
FBCO
Outperform
ServiceMaster CFO transition 'not unnerving,' says Credit Suisse
Credit Suisse analyst Anjaneya Singh notes that ServiceMaster announced that CFO Alan Haughie will retire from the company in March, with Anthony DiLucente taking his place. While the analyst was surprised to hear of the CFO transition considering Haughie's relatively short tenure, Singh was "relieved to learn" that his departure comes as a result of a personal decision and "finds comfort" in the fact that DiLucente comes with significant financial and operational acumen developed at a diverse set of companies. He reiterates an Outperform rating and $43 price target on the shares.
08/22/16
MSCO
08/22/16
NO CHANGE
Target $45
MSCO
Overweight
ServiceMaster selloff an overreaction, says Morgan Stanley
Morgan Stanley analyst Toni Kaplan said the selloff in ServiceMaster shares following the resignation of Terminix president William Derwin is an overreaction. The analyst said the segment has been underperforming and believes the market is not expected a significant near-term acceleration and that a fresh look at Terminix's strategy can result in new ideas and be a catalyst for growth. Kaplan reiterates ServiceMaster's Overweight rating and $45 price target and said valuation is compelling.
09/19/16
NOMU
09/19/16
DOWNGRADE
Target $31
NOMU
Reduce
ServiceMaster downgraded to Reduce from Neutral at Nomura
Nomura analyst Dan Dolev downgraded ServiceMaster to Hold and lowered its price target to $31 from $36. The analyst expects weak growth at Terminex to linger given it overexposure to slower growth termite, reduced customer and employee retention, and headwinds from Alterra M&A as it starts lapping in November. Dolev said expects increased marketing spend for AHS, or home warranty, to maintain growth amid deteriorating levels of customer reviews.

TODAY'S FREE FLY STORIES

PCTY

Paylocity

$45.10

-1.06 (-2.30%)

, PAYX

Paychex

$54.98

-1.26 (-2.24%)

18:11
08/17/17
08/17
18:11
08/17/17
18:11
Hot Stocks
Paylocity announces Michael Haske's promotion to president & COO »

Paylocity announced that…

PCTY

Paylocity

$45.10

-1.06 (-2.30%)

PAYX

Paychex

$54.98

-1.26 (-2.24%)

ADP

ADP

$104.68

-6.42 (-5.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

  • 12

    Sep

  • 30

    Oct

  • 17

    Aug

SN

Sanchez Energy

$4.87

-0.145 (-2.89%)

18:04
08/17/17
08/17
18:04
08/17/17
18:04
Hot Stocks
Sanchez Energy to sell Javelina asset in Eagle Ford shale for about $105M »

Sanchez Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 16

    May

BABA

Alibaba

$163.92

4.42 (2.77%)

17:50
08/17/17
08/17
17:50
08/17/17
17:50
Recommendations
Alibaba analyst commentary  »

Alibaba price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 18

    Aug

ASYS

Amtech Systems

$10.14

-0.51 (-4.79%)

17:48
08/17/17
08/17
17:48
08/17/17
17:48
Syndicate
Amtech Systems announces common stock offering, no amount given »

Amtech Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPCAY

Cathay Pacific

$7.47

0.15 (2.05%)

17:47
08/17/17
08/17
17:47
08/17/17
17:47
Upgrade
Cathay Pacific rating change  »

Cathay Pacific upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$177.25

-0.83 (-0.47%)

17:32
08/17/17
08/17
17:32
08/17/17
17:32
Hot Stocks
Raytheon awarded $104.8M government contract »

Raytheon Missile Systems,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPWH

Sportsman's Warehouse

$3.46

-0.12 (-3.35%)

, GLOB

Globant

$42.26

-0.64 (-1.49%)

17:32
08/17/17
08/17
17:32
08/17/17
17:32
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

SPWH

Sportsman's Warehouse

$3.46

-0.12 (-3.35%)

GLOB

Globant

$42.26

-0.64 (-1.49%)

ROST

Ross Stores

$53.33

-1.04 (-1.91%)

GPS

Gap

$22.68

0.11 (0.49%)

AMAT

Applied Materials

$43.12

-1.34 (-3.01%)

FLDM

Fluidigm

$3.60

-0.04 (-1.10%)

SENS

Senseonics

$2.44

0.02 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

  • 17

    Aug

  • 21

    Aug

  • 23

    Aug

  • 18

    Aug

LMT

Lockheed Martin

$301.42

-4.38 (-1.43%)

17:32
08/17/17
08/17
17:32
08/17/17
17:32
Hot Stocks
Lockheed Martin, others awarded $499M government contract »

Lockheed Martin, Fort…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

CTRL

Control4

$22.27

-0.9 (-3.88%)

, AMRI

Albany Molecular

$21.74

-0.01 (-0.05%)

17:21
08/17/17
08/17
17:21
08/17/17
17:21
Hot Stocks
Control4 to replace Albany Molecular in S&P 600 at open on 8/22 »

The Carlyle Group (CG)…

CTRL

Control4

$22.27

-0.9 (-3.88%)

AMRI

Albany Molecular

$21.74

-0.01 (-0.05%)

CG

Carlyle Group

$21.20

-0.2 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

CI

Cigna

$178.03

-1.83 (-1.02%)

17:15
08/17/17
08/17
17:15
08/17/17
17:15
Hot Stocks
Cigna's Bacus sells 2,236 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

17:09
08/17/17
08/17
17:09
08/17/17
17:09
General news
Sen. Corker: Trump has not demonstrated competence to be president »

According to various…

BTU

Peabody Energy

$27.94

-0.27 (-0.96%)

17:07
08/17/17
08/17
17:07
08/17/17
17:07
Syndicate
Peabody Energy files to sell 12.8M shares of common stock for holders »

Peabody Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEMI

Chembio Diagnostics

$6.05

-0.1 (-1.63%)

17:02
08/17/17
08/17
17:02
08/17/17
17:02
Hot Stocks
Chembio Diagnostics CFO Richard Larkin to retire »

Chembio Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRMT

America's Car-Mart

$36.90

-0.65 (-1.73%)

17:01
08/17/17
08/17
17:01
08/17/17
17:01
Earnings
America's Car-Mart reports Q1 EPS 90c, consensus 91c »

Reports Q1 revenue $146M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$35.00

-0.75 (-2.10%)

16:59
08/17/17
08/17
16:59
08/17/17
16:59
Hot Stocks
General Motors' Jacoby sells 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBI

CB&I

$9.78

-0.19 (-1.91%)

, FLR

Fluor

$37.77

-0.67 (-1.74%)

16:59
08/17/17
08/17
16:59
08/17/17
16:59
Hot Stocks
President Donald Trump shelves plans to create infrastructure advisory council »

According to various…

CBI

CB&I

$9.78

-0.19 (-1.91%)

FLR

Fluor

$37.77

-0.67 (-1.74%)

ACM

Aecom

$31.09

-0.43 (-1.36%)

MTZ

MasTec

$39.20

0.45 (1.16%)

CCI

Crown Castle

$104.14

0.35 (0.34%)

JEC

Jacobs Engineering

$50.25

-0.8 (-1.57%)

MLM

Martin Marietta

$200.41

-4.7 (-2.29%)

USCR

U.S. Concrete

$77.20

-0.9 (-1.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

CQP

Cheniere Energy Partners

$28.08

-0.08 (-0.28%)

16:53
08/17/17
08/17
16:53
08/17/17
16:53
Syndicate
Breaking Syndicate news story on Cheniere Energy Partners »

Cheniere Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$54.83

-1.1 (-1.97%)

16:50
08/17/17
08/17
16:50
08/17/17
16:50
Hot Stocks
Dillard's raises quarterly dividend to 10c from 7c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABTL

Autobytel

$8.30

-0.12 (-1.43%)

16:46
08/17/17
08/17
16:46
08/17/17
16:46
Hot Stocks
Autobytel announces purchases under stock repurchase authorization »

Autobytel announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBL

GAMCO Investors

$29.41

-0.4 (-1.34%)

, CMT

Core Molding

$21.07

-0.36 (-1.68%)

16:43
08/17/17
08/17
16:43
08/17/17
16:43
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, Core Molding »

Gabelli reports 10.94%…

GBL

GAMCO Investors

$29.41

-0.4 (-1.34%)

CMT

Core Molding

$21.07

-0.36 (-1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

GUID

Guidance Software

16:41
08/17/17
08/17
16:41
08/17/17
16:41
Hot Stocks
Breaking Hot Stocks news story on Guidance Software »

Soros Fund Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBL

GAMCO Investors

$29.41

-0.4 (-1.34%)

, MTRN

Materion

$37.00

-1.1 (-2.89%)

16:41
08/17/17
08/17
16:41
08/17/17
16:41
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, Materion »

Gabelli reports 6.66%…

GBL

GAMCO Investors

$29.41

-0.4 (-1.34%)

MTRN

Materion

$37.00

-1.1 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 14

    Nov

FALC

FalconStor

$0.19

-0.004 (-2.12%)

16:41
08/17/17
08/17
16:41
08/17/17
16:41
Hot Stocks
FalconStor announces Todd Brooks as CEO and Patrick McClain as CFO »

FalconStor announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:36
08/17/17
08/17
16:36
08/17/17
16:36
General news
Fed Balance Sheet Level data reported »

Week of 8/16 Fed Balance…

16:36
08/17/17
08/17
16:36
08/17/17
16:36
General news
Money Supply M2 Weekly Change data reported »

Week of 8/7 Money Supply…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.